X0206 3 2020-09-15 0 0001634379 Metacrine, Inc. MTCR 0001329161 Adelman Robert J C/O METACRINE, INC. 3985 SORRENTO VALLEY BLVD., SUITE C SAN DIEGO CA 92121 1 0 1 0 Series A Convertible Preferred Stock Common Stock 1960784 I See footnote Series B Convertible Preferred Stock Common Stock 472250 I See footnote Series C Convertible Preferred Stock Common Stock 396089 I See footnote Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") are convertible into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock has no expiration date. The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. See Power of Attorney attached as Exhibit 24.1. Robert Adelman, by: /s/ David Pezeshki, Attorney-in-fact 2020-09-15